Candesartan v placebo for chronic heart failure (CHF) at median 37.7 months*
| Trial | Outcomes | Candesartan | Placebo | Unadjusted HR (95% CI) | Adjusted analysis† | ||
|---|---|---|---|---|---|---|---|
| HR (CI) | RRR (CI) | NNT (CI) | |||||
| *Composite endpoint = cardiovascular death or hospital admission for worsening CHF; CHARM = Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity; HR = hazard ratio. Other abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article using Cox proportional hazards model. | |||||||
| †Adjusted for baseline covariates, including patients’ characteristics, heart disease risk factors, medical history, and medical treatment. | |||||||
| Overall | All cause mortality | 23% | 25% | 0.91 (0.83 to 1.00) | 0.90 (0.82 to 0.99) | 8.8% (0.9 to 16) | 46 (26 to 463) |
| CHARM-Added | Composite | 38% | 42% | 0.85 (0.75 to 0.96) | 0.85 (0.75 to 0.96) | 12% (3 to 20) | 21 (12 to 79) |
| CHARM-Alternative | Composite | 33% | 40% | 0.77 (0.67 to 0.89) | 0.70 (0.60 to 0.81) | 25% (15 to 34) | 11 (8 to 17) |
| CHARM-Preserved | Composite | 22% | 24% | 0.89 (0.77 to 1.03) | 0.86 (0.74 to 1.00) | 12% (0 to 23) | Borderline significance |